Literature DB >> 22762478

Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats.

Christopher Bishop1, Jessica A George, William Buchta, Adam A Goldenberg, Mohamed Mohamed, Sando O Dickinson, Satie Eissa, Karen L Eskow Jaunarajs.   

Abstract

Long-term dopamine replacement therapy with l-DOPA in Parkinson's disease often leads to the development of abnormal involuntary movements known as l-DOPA-induced dyskinesia. Growing evidence suggests that, following dopamine cell loss, serotonin neurons acting as surrogates for dopaminergic processes take up l-DOPA, convert it to dopamine and release it in an unregulated fashion that precipitates dyskinesia. Although most studies have focused on serotonin 5-HT(1) receptor stimulation as an antidyskinetic strategy, targeting the serotonin transporter modulation of dopamine activity has been overlooked. Therefore, in the current study, selective serotonin reuptake inhibitors were tested for their ability to reduce l-DOPA- and apomorphine-induced dyskinesia. In Experiments 1 and 2, hemi-parkinsonian rats were primed with l-DOPA until stable dyskinesia developed. Rats in Experiment 1 were administered the selective serotonin reuptake inhibitors paroxetine, citalopram or fluoxetine, followed by l-DOPA. Abnormal involuntary movements and forepaw adjusting steps were recorded to determine the effects of these compounds on dyskinesia and motor performance, respectively. Brains were collected on the final test day, after which striatal and raphe monoamines were examined via high-performance liquid chromatography. In Experiment 2, dyskinesias were measured after selective serotonin reuptake inhibitors and apomorphine. Serotonin reuptake inhibitors dose-dependently attenuated l-DOPA- but not apomorphine-induced dyskinesia, and preserved l-DOPA efficacy. Neurochemically, serotonin transporter inhibition enhanced striatal and raphe serotonin levels and reduced its turnover, indicating a potential mechanism of action. The present results support targeting serotonin transporters to improve Parkinson's disease treatment and provide further evidence for the role of the serotonin system in l-DOPA's effects.
© 2012 The Authors. European Journal of Neuroscience © 2012 Federation of European Neuroscience Societies and Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22762478      PMCID: PMC3445783          DOI: 10.1111/j.1460-9568.2012.08202.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  70 in total

1.  Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications.

Authors:  L Verhagen Metman; E R Locatelli; D Bravi; M M Mouradian; T N Chase
Journal:  Neurology       Date:  1997-02       Impact factor: 9.910

Review 2.  Movement disorders associated with the serotonin selective reuptake inhibitors.

Authors:  R J Leo
Journal:  J Clin Psychiatry       Date:  1996-10       Impact factor: 4.384

3.  A semiautomated analysis method for catecholamines, indoleamines, and some prominent metabolites in microdissected regions of the nervous system: an isocratic HPLC technique employing coulometric detection and minimal sample preparation.

Authors:  I C Kilpatrick; M W Jones; O T Phillipson
Journal:  J Neurochem       Date:  1986-06       Impact factor: 5.372

4.  Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model.

Authors:  Andrzej Dekundy; Martin Lundblad; Wojciech Danysz; M Angela Cenci
Journal:  Behav Brain Res       Date:  2007-01-23       Impact factor: 3.332

5.  Short-term paroxetine treatment does not alter the motor response to levodopa in PD.

Authors:  Kathryn A Chung; Nichole E Carlson; John G Nutt
Journal:  Neurology       Date:  2005-05-24       Impact factor: 9.910

6.  Levodopa-induced dyskinesias are improved by fluoxetine.

Authors:  F Durif; M Vidailhet; A M Bonnet; J Blin; Y Agid
Journal:  Neurology       Date:  1995-10       Impact factor: 9.910

7.  Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test.

Authors:  M Olsson; G Nikkhah; C Bentlage; A Björklund
Journal:  J Neurosci       Date:  1995-05       Impact factor: 6.167

8.  Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson's disease.

Authors:  Sylvia Navailles; Bernard Bioulac; Christian Gross; Philippe De Deurwaerdère
Journal:  Neurobiol Dis       Date:  2010-01-22       Impact factor: 5.996

9.  Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats.

Authors:  Christopher Bishop; David M Krolewski; Karen L Eskow; Christopher J Barnum; Kristin B Dupre; Terrence Deak; Paul D Walker
Journal:  J Neurosci Res       Date:  2009-05-15       Impact factor: 4.164

10.  Does fluoxetine exacerbate Parkinson's disease?

Authors:  C F Caley; J H Friedman
Journal:  J Clin Psychiatry       Date:  1992-08       Impact factor: 4.384

View more
  23 in total

1.  D-512, a novel dopamine D2/3 receptor agonist, demonstrates greater anti-Parkinsonian efficacy than ropinirole in Parkinsonian rats.

Authors:  David Lindenbach; Banibrata Das; Melissa M Conti; Samantha M Meadows; Aloke K Dutta; Christopher Bishop
Journal:  Br J Pharmacol       Date:  2017-08-11       Impact factor: 8.739

Review 2.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

Review 3.  Multisite intracerebral microdialysis to study the mechanism of L-DOPA induced dopamine and serotonin release in the parkinsonian brain.

Authors:  S Navailles; M Lagière; A Contini; P De Deurwaerdère
Journal:  ACS Chem Neurosci       Date:  2013-04-15       Impact factor: 4.418

Review 4.  Catecholamine/Serotonin interactions: systems thinking for brain function and disease.

Authors:  Julie G Hensler; Francesc Artigas; Analía Bortolozzi; Lynette C Daws; Philippe De Deurwaerdère; Léa Milan; Sylvia Navailles; Wouter Koek
Journal:  Adv Pharmacol       Date:  2013

Review 5.  The serotonergic system in L-DOPA-induced dyskinesia: pre-clinical evidence and clinical perspective.

Authors:  Manolo Carta; Anders Björklund
Journal:  J Neural Transm (Vienna)       Date:  2018-02-26       Impact factor: 3.575

Review 6.  Serotonergic targets for the treatment of L-DOPA-induced dyskinesia.

Authors:  Kathryn Lanza; Christopher Bishop
Journal:  J Neural Transm (Vienna)       Date:  2018-01-05       Impact factor: 3.575

Review 7.  Neuroinflammation in L-DOPA-induced dyskinesia: beyond the immune function.

Authors:  Augusta Pisanu; Laura Boi; Giovanna Mulas; Saturnino Spiga; Sandro Fenu; Anna R Carta
Journal:  J Neural Transm (Vienna)       Date:  2018-03-14       Impact factor: 3.575

8.  Side effect profile of 5-HT treatments for Parkinson's disease and L-DOPA-induced dyskinesia in rats.

Authors:  D Lindenbach; N Palumbo; C Y Ostock; N Vilceus; M M Conti; C Bishop
Journal:  Br J Pharmacol       Date:  2014-11-24       Impact factor: 8.739

Review 9.  The serotonergic system in motor and non-motor manifestations of Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox
Journal:  Exp Brain Res       Date:  2013-06-28       Impact factor: 1.972

10.  Effects of prolonged selective serotonin reuptake inhibition on the development and expression of L-DOPA-induced dyskinesia in hemi-parkinsonian rats.

Authors:  Melissa M Conti; Corinne Y Ostock; David Lindenbach; Adam A Goldenberg; Elias Kampton; Rich Dell'isola; Aaron C Katzman; Christopher Bishop
Journal:  Neuropharmacology       Date:  2013-09-22       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.